To assess whether angiotensin-converting enzyme (ACE) inhibitors and other hypertensive drugs are superior to alternative agents for the prevention of cardiovascular events in patients with hypertension and type 2 diabetes.
number of outcome events occurring in each treatment group.
For the combined outcome of cardiovascular events, the authors adopted the definition used in each trial. The authors calculated the total number of cardiovascular events by adding the number of fatal and nonfatal acute myocardial infarctions and strokes, the number of congestive heart failure events, and the number of sudden deaths. This method is likely to have slightly overestimated the number of patients with cardiovascular events in the UK Prospective Diabetes Study (UKPDS), because more than one event may have occurred in a single patient.
In one trial where the number of events in patients with diabetes was not reported, the authors estimated them using the sample size, the relative risk (RR), the 95% confidence intervals (CIs), and the P-value for the difference between the two treatment groups.
Methods of synthesis
How were the studies combined? A pooled RR was calculated, along with 95% CIs, using the method of Peto et al. (see Other Publications of Related Interest no.1).
How were differences between studies investigated?
The differences between studies were assessed using Cochran's chi-squared statistic (see Other Publications of Related Interest no.2). In addition, to identify potential outliers, the authors tested the heterogeneity of the trial results for individual outcomes of interest through iterative analyses.
Results of the review
Four RCTs with 2,180 participants were included in the review: 1,133 participants were randomised to an ACE inhibitor and 1,047 were randomised to an alternative agent.
The cumulative results of 3 trials showed a statistically-significant benefit of ACE inhibitors on the outcome of acute myocardial infarction, compared with alternative treatments: there was a 63% reduction (P<0.001) and the RR was 0.37 (95% CI: 0.24, 0.57).
The cumulative results of 3 trials showed a statistically-significant benefit of ACE inhibitors on the outcome of cardiovascular events, compared with alternative treatments: there was a 51% reduction (P<0.001) and the RR was 0.49 (95% CI: 0.36, 0.67).
The cumulative results of 3 trials showed a statistically-significant benefit of ACE inhibitors on the outcome of allcause mortality, compared with alternative treatments: there was a 62% reduction (P=0.010) and the RR was 0.57 (95% CI: 0.38, 0.87).
These findings were not observed in the UKPDS study (atenolol compared with captopril). The ACE inhibitors did not appear to be superior to other agents for the outcome of stroke in any of the trials, RR 0.76 (95% CI: 0.48, 1.22).
None of the findings were explained by differences in blood-pressure control.
The heterogeneity test was significant for both of the outcomes of acute myocardial infarction and cardiovascular events when the data of the UKPDS trial were combined with the other 3 trials (P<0.001). The heterogeneity test was not, however, significant when the UKPDS trial was excluded from the meta-analysis.
